|
|
 |
|
Viewing report
|
|
|
|
Blockbuster Drugs: A 2005-2014 Forecast
Decision Resources, Inc., Dec 2005, Pages: 79
Blockbuster drugs--drugs with annual sales topping $1 billion--accounted for approximately 30% of the pharmaceutical industry's total sales in 2004. In the next several years, patent expiries on many blockbusters will fundamentally alter the sales outlook for leading pharmaceutical companies. What strategies will companies pursue to replace sales lost to generics competition? Pursuit of new blockbusters is one approach, though the shift taking place in the therapeutic areas ripe for blockbuster development means that some companies must adjust their core competencies.
In this report, we identify drugs that we believe will achieve blockbuster status during a 2005-2014 forecast period, presenting them by therapeutic area and describing each drug's mechanism of action, performance in clinical trials, strengths and weaknesses, and competitive opportunities and threats. We also point to other drugs that are contenders for blockbuster status.
Customers who bought this item also bought
Streamlining Clinical Trials
Current Clinical Trials: Rheumatology
Emerging Blockbusters: 2009's Most Promising Drugs and the Future of the Blockbuster Model
Clinical Trials in India
Innovations and Trends in Clinical Trials - Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
Clinical Trials Market in Russia
Commercial Insight: Anticonvulsants - Non-epilepsy Label Expansions Provide Blockbuster Potential
Industry Insight Clinical Trials in India
Conducting Clinical Trials in Emerging Markets
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Outsourcing Clinical Trials: A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index
Booming Clinical Trials Market in India
|
|
|
|
